Regular Digoxin users had a 24% lower risk of prostate cancer

Digoxin alters enzymatic pathways for sodium and potassium in heart cells that slows the heart rate while improving pumping action. Recently, a robotic surgery expert who is also a urologic oncologist, said that Digoxin could potentially do the same for prostate cancer.

According to a study by scientists at Johns Hopkins men who used this cardiac drug had a 24 percent lower risk for prostate cancer. The study concluded Digoxin does show promise for treatment